Company news
Kura Oncology, Inc. (NASDAQ:KURA) news
Every Kura Oncology, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Kura Oncology Reports Second Quarter 2026 Financial Results
August 12, 2026
Kura Oncology to Report Second Quarter Financial Results
August 5, 2026
Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Pa...
July 27, 2026
Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in R...
July 14, 2026
Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML
June 11, 2026
Kura Oncology Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
June 8, 2026
Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development ...
June 3, 2026
Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R ...
June 2, 2026
Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors
May 26, 2026
Kura Oncology to Present at TD Cowen 7th Annual Oncology Innovation Summit
May 19, 2026
Kura Oncology Reports First Quarter 2026 Financial Results
May 12, 2026
Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress
May 12, 2026
Kura Oncology to Report First Quarter 2026 Financial Results
May 5, 2026
Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML
April 24, 2026
Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previou...
April 17, 2026
Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabo...
April 9, 2026
Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results
March 5, 2026
Kura Oncology to Report Fourth Quarter and Full Year 2025 Financial Results
February 26, 2026
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 6, 2026
Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones
January 11, 2026
Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and R...
December 8, 2025
Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with ...
December 3, 2025
First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreemen...
December 2, 2025
KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML)
November 25, 2025
Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults ...
November 13, 2025
Kura Oncology to Participate in Upcoming Investor Conference
November 12, 2025
Kura Oncology Reports Third Quarter 2025 Financial Results
November 4, 2025
Kura Oncology and Kyowa Kirin Announce Presentations of Ziftomenib Ven/Aza Combination Data in Frontline and Relapsed/Refractory NPM1-m o...
November 3, 2025
Kura Oncology Receives Second $30 Million Development Milestone Payment in AML Menin Inhibitor Program With Kyowa Kirin
November 3, 2025
Kura Oncology to Report Third Quarter 2025 Financial Results
October 28, 2025
Kura Oncology Receives $30 Million Development Milestone Payment in Ziftomenib AML Program with Kyowa Kirin
October 24, 2025
Kura Oncology Announces Preliminary Data from Its Farnesyl Transferase Inhibitor (FTI) Programs at the 2025 European Society for Medical ...
October 18, 2025
Kura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and FLT3 Mutations in Patients with Newly Diagnose...
October 1, 2025
Kura Oncology and Kyowa Kirin Announce First Patient Dosed in Pivotal Phase 3 KOMET-017 Trial of Ziftomenib for Frontline Acute Myeloid L...
September 29, 2025
Kura Oncology and Kyowa Kirin Announce Publication of Pivotal Ziftomenib Data in Relapsed/Refractory NPM1-Mutated AML in the Journal of C...
September 25, 2025
Kura Oncology Highlights Preclinical Data Demonstrating Potential of Farnesyl Transferase Inhibitors to Overcome Drug Resistance in Combi...
September 16, 2025
Kura Oncology to Host Virtual Investor and Analyst Events on Farnesyl Transferase Inhibitor Program
September 3, 2025
Kura Oncology to Participate in Three Upcoming Investor Conferences
August 28, 2025
Kura Oncology Reports Second Quarter 2025 Financial Results
August 7, 2025
OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee
August 6, 2025
Kura Oncology to Report Second Quarter 2025 Financial Results
July 31, 2025
Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology ...
June 12, 2025
Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting
June 2, 2025
Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed ...
June 1, 2025
Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting
May 22, 2025
Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (...
May 14, 2025
Kura Oncology to Participate in Bank of America Securities Healthcare Conference
May 6, 2025
Kura Oncology Reports First Quarter 2025 Financial Results
May 1, 2025
Kura Oncology Announces First Patients Dosed in Phase 1 Combination Trial of Ziftomenib for the Treatment of Advanced GIST
April 28, 2025
Kura Oncology to Report First Quarter 2025 Financial Results
April 24, 2025